Rua Diagnostics
RUA Diagnostics develops a portable micro gas chromatography (µGC) device that analyzes volatile organic compounds (VOCs) in breath for non-invasive, rapid diagnostics. Their technology offers parts-per-trillion sensitivity previously only available in large labs, delivering diagnostic results in 30 minutes. Powered by advanced photo-ionization and microfluidics, combined with AI and machine learning, the platform screens multiple diseases from a single breath sample, enabling early detection, monitoring, and personalized care. The company focuses on minimizing demographic biases and expanding diagnostic capabilities via a connected cloud platform. Key diseases targeted include COVID-19, lung cancer, ARDS, colorectal cancer, and asthma, with high diagnostic accuracy demonstrated in landmark studies. RUA Diagnostics is positioned as a pioneer in point-of-care breath diagnostics, aiming to revolutionize healthcare with fast, precise, and accessible testing.
Rua Diagnostics
RUA Diagnostics develops a portable micro gas chromatography (µGC) device that analyzes volatile organic compounds (VOCs) in breath for non-invasive, rapid diagnostics. Their technology offers parts-per-trillion sensitivity previously only available in large labs, delivering diagnostic results in 30 minutes. Powered by advanced photo-ionization and microfluidics, combined with AI and machine learning, the platform screens multiple diseases from a single breath sample, enabling early detection, monitoring, and personalized care. The company focuses on minimizing demographic biases and expanding diagnostic capabilities via a connected cloud platform. Key diseases targeted include COVID-19, lung cancer, ARDS, colorectal cancer, and asthma, with high diagnostic accuracy demonstrated in landmark studies. RUA Diagnostics is positioned as a pioneer in point-of-care breath diagnostics, aiming to revolutionize healthcare with fast, precise, and accessible testing.